USP22-IN-1 (20 mg/kg; i.p.; twice a day for 5 days) enhances the anti-tumor immunity in mice [1]. The study used male C57BL/6 mice (6-8 weeks old) with LLC1 cells [1]. The dosage administered was 20 mg/kg via intraperitoneal injection, given twice a day for 5 days [1]. The results showed an improvement in anti-tumor immunity, leading to decreased tumor cell counts, reduced viability, and inhibited tumor growth [1].
In Vitro
USP22-IN-1 (compound S02) reduces the expression of Foxp3 MFI and cell viability in a dose-dependent manner at concentrations of 0, 5, 10, 15, 20, and 25 µg/mL [1]. At a concentration of 10 µg/mL and during an incubation time of 0-12 hours, USP22-IN-1 decreases the expression levels of FOXP3, USP22 protein, and Foxp3 mRNA in iTreg cells [1]. The Cell Viability Assay showed that cell survival was inhibited in a dose-dependent manner [1]. Western Blot Analysis revealed that the expression of FOXP3 and USP22 decreased in a time-dependent manner when cells were treated with 10 µg/mL of USP22-IN-1 [1].
Kinase Assay
Cell Assay
Animal Administration
References
[1]. Deyu FANG, et al. Inhibitors of ubiquitin specific peptidase 22 (usp22) and uses thereof for treating diseases and disorders. WO2022226402A1.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
